Alzheimer’s is one of the most horrible diseases because it robs a person of their personality and memory, and it eventually leads to them losing the battle with the disease.

There are currently over 5.8 million people in the U.S. living with it, and it is the sixth-largest life-taker in the country.

The disease devastates many families, and it is estimated that Alzheimer’s and other forms of dementia will cost the U.S. $290 billion dollars this year alone.

Even though there have been over 200 attempts to find a cure for the disease, all of them have been unsuccessful, and the clinical trial termination rate is 98%.

Alzheimer’s disease is caused by plaque deposits that develop in the brain and they become toxic to brain cells, and one of the biggest problems to finding a cure for it is that it’s currently impossible to clear out the deposits from the brain tissue. Since scientists are aware of this, they have turned their attention to prevention and early detection.

However, one very encouraging development has recently come out by Dr. Chang Yi Wang, a prolific bio-inventor.

One of her biggest successes so far has been a foot-and-mouth vaccine for pigs that have been administered over three billion times.

United Neuroscience, a biotech company founded by Yi, her daughter Mei Mei Hu, and her son-in-law Louis Reese, announced the results of an IIa clinical trial on UB-311, an Alzheimer’s vaccine.

The vaccine contains synthetic versions of amino acid chains that trigger antibodies to attack Alzheimer’s protein in the blood. The vaccine is a huge breakthrough because it attacks Alzheimer’s protein without creating any side effects.

Yi told Wired that they were able to generate some antibodies in all patients, which is very unusual for vaccines, and she noted that they’re talking about almost a 100 percent response rate.

According to the researchers, the vaccine can delay the onset of the disease by five years, which can be a godsend for people with the disease and their families.

The company currently works on its next clinical trial of the vaccine. It has already invested over $100 million in development, and the company’s ultimate goal is to create a host of vaccines that will be administered to protect people from chronic illness.